Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03967249 · ClinicalTrials.gov registry record · Phase 2
Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
A Phase 2 study, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT03967249 is a Phase 2 study that has completed, run by Ionis Pharmaceuticals. The registered enrollment target is 39 participants.
The verdict
NCT03967249, a Phase 2 study, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and efficacy of extended dosing with IONIS GHR-LRx in participants with acromegaly as add-on to somatostatin receptor ligands (SRL) therapy.
Interventions
- DRUG IONIS GHR-LRx
- DRUG Somatostatin Receptor Ligand (SRL)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2019-07-25 |
| Est. Completion | 2022-07-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03967249
The ClinicalTrials.gov registry entry for NCT03967249 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which IONIS GHR-LRx is the first listed.
NCT03967249 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03967249 about?
NCT03967249 is a clinical study titled "Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands". The purpose of this study is to assess the safety and efficacy of extended dosing with IONIS GHR-LRx in participants with acromegaly as add-on to somatostatin receptor ligands (SRL) therapy.
What is the current status of trial NCT03967249?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2019-07-25. Estimated completion is 2022-07-07.
What interventions are being tested in trial NCT03967249?
The interventions under investigation include: IONIS GHR-LRx (DRUG), Somatostatin Receptor Ligand (SRL) (DRUG).
Who is sponsoring clinical trial NCT03967249?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.